Edition:
United States

TBG Diagnostics Ltd (PGLA.PQ)

PGLA.PQ on OTC Markets Group

0.20USD
5 Aug 2016
Change (% chg)

-- (--)
Prev Close
$0.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$0.00
52-wk Low
$0.00

Summary

Name Age Since Current Position

Indrajit Arulampalam

2016 Executive Chairman of the Board

Leslie Tillack

Chief Executive Officer - Pharmasynth

Willy Hsu

2019 Chief Operating Officer

Lee Horobin

2012 General Manager - Finance

Keith Dredge

2013 Director of Drug Development

Fleur Lankesheer

Director - Business Development and Legal

Justyn Stedwell

2016 Company Secretary

Wang Hsi-Kai

2018 Director

Shi-Chung Chang

2015 Non-Executive Director

Eugene Cheng

Emily Lee

2015 Non-Executive Director

Biographies

Name Description

Indrajit Arulampalam

Mr. Indrajit (Jitto) Solomon Arulampalam is Executive Chairman of the Board of the Company. Mr. Arulampalam is currently Executive Chairman of Euro Petroleum Limited, an unlisted Australian public company in the process of commercializing one of the last remaining world-class phosphate deposits with an Asian fertilizer company, as well as merging the company’s graphite operations with an ASX-listed graphite explorer. Mr. Arulampalam comes to the Company with considerable experience as a director of various listed public companies in Australia. He has previously held positions as Chair of Fortis Mining, Great Western Exploration, Medicvision Limited, and Atos Wellness Limited. Mr. Arulamparam holds a Bachelor of Business Administration from Curtin University.

Leslie Tillack

Willy Hsu

Mr. Willy Hsu is Chief Operating Officer of the Company. He has ten years’ experience as Marketing and Sales Manager with the Company’s wholly owned subsidiary TBG Biotechnology Corp focusing on the global sales and marketing of Human Leukocyte Antigen (HLA) genotyping. Mr. Hsu has a strong scientific research background in both immunology and Bioinformatics. He holds a Bachelor of Science in Biochemistry from the University of California-Davis, Davis, CA, USA, Certification in the Business Development Program with emphasis in Entrepreneurship from the Graduate school of Management, University of California-Davis, Davis, CA. Mr Hsu has also attained a Ph.D. in Immunology, University of California-Davis, Davis, CA, USA.

Lee Horobin

Mr. Lee Horobin serves as General Manager - Finance of Progen Pharmaceuticals Limited since August 23, 2012. He served as Company Secretary from March 1, 2010 to May 24, 2010, and Acting General Manager - Finance from March 1, 2010 to May 2010. He has commenced with Progen on an interim basis due to an extended period of absence of Mr. Paul Dixon. Mr. Horobin is a member of CPA Australia and has held company secretarial positions in previous roles.

Keith Dredge

Dr. Keith Dredge, Ph.D., is Director of Drug Development at Progen Pharmaceuticals Ltd. Mr. Dredge is a UK and European Registered Toxicologist with over 15 years of experience in drug development. He initially joined Progen in 2006 but returned in August 2013 as Director of Drug Development. In this role, he is responsible for the progression of drug candidates through Progen's pipeline. He has authored over 30 internationally-recognized scientific publications including several on Progen's proprietary technologies, particularly PG545 in Molecular Cancer Therapeutics, PLoS One, British Journal of Cancer and Investigational New Drugs. Previously, he held a management position at TetraQ, a GLP-recognised contract research organization at The University of Queensland (UQ) and academic positions at UQ and at St. George's University of London, UK where he published the first articles on Celgene's Revlimid and Pomalyst, now approved anti-cancer drugs. He obtained his Ph.D. in Pharmacology from the National University of Ireland, Galway and B.Sc. (Hons) in Toxicology from the Athlone Institute of Technology (Ireland). He is also a member of the American Association of Cancer Research (AACR).

Fleur Lankesheer

Justyn Stedwell

Mr. Justyn Stedwell is the Company Secretary of the Company. Justyn is a professional Company Secretary consultant with ten years’ experience as a Company Secretary of ASX listed companies. He has completed a Bachelor of Commerce (Economics & Management) from Monash University, a Graduate Diploma of Accounting from Deakin University and a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia.

Wang Hsi-Kai

Shi-Chung Chang

Dr. Shi-Chung Chang M.D., is Non-Executive Director of the Company. Dr. Chang holds a medical degree from the National Taiwan University (NTU) college of Medicine, and a Ph.D. from the Department of Surgery, London Medical School, University of London. Dr Chang is the Chairman and CEO of Taiwan-based Medigen Biotechnology Corporation.

Eugene Cheng

Mr. Eugene Cheng was Non-Executive Director of the Company. He is the Group Chief Officer Operation (COO) of TBG Diagnostics Limited (TDL). Mr. Cheng joined Medigen Biotechnology Corp in 2004 and initiated the molecular diagnostics business in 2006 by the acquisition of Texas Biogene, Inc. (TBG), a biotech company based in Dallas, USA, specializing in the development of tissue typing products that are marketed under the TBG brand. Mr. Cheng also spearheaded the acquisition of Haoyuan in Shanghai, China, in 2007, and its divestiture to Perkin Elmer in 2012 when Haoyuan became the leading local brand in the NAT blood screening market in China. Armed with the knowledge and experience in the Chinese market, TBG aims to become one of the leading molecular diagnostics brands in China within 5 years. As part of the strategy to achieve that goal, TBG was re-listed on ASX through a reverse merger with Progen Pharmaceutical (PGL) in February 2016. Currently, Mr. Cheng serves as a director of both Medigen and TDL.

Emily Lee

Basic Compensation